CLINICAL_TRIALS
trial_result
· 2021-02-24
Clinical Trial Update: Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia [Phase 2]
Summary
A Phase 2 clinical trial evaluating bortezomib and Doxil for acute myeloid leukemia has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Joseph Tuscano | Conditions: Acute Myelogenous Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-02-24